Tempest Therapeutics, Inc. · NASDAQ:TPST
Tempest Therapeutics — Millendo Therapeutics — Corporate Update (April 2020)
8 slides from Tempest Therapeutics's corporate update, Apr 6, 2020
Slide 1: Topline Results for ZEPHYR Phase 2b Study of Livoletide
Topline Results for ZEPHYR Phase 2b Study of Livoletide April 6, 2020
Slide 2: Introduction
Introduction Connie Chang, Vice President, Corporate Affairs
Slide 3: Cautionary Statement Regarding Forward-Looking Statements
A Cautionary Statement Regarding Forward-Looking Statements Certain statements contained inthis presentation regarding matters that are nat historical facts are forward-looking statements within the meaning of Section 27A, ofthe Securties Act of 1933, as amended, and Section 21E of the Securities Ex
Slide 4: Topline Results for Pivotal Phase 2b Study of Livoletide in Prader-Willi Syndrome
Topline Results for Pivotal Phase 2b Study of Livoletide in Prader - Willi Syndrome Julia C. Owens, Ph.D., President and Chief Executive Officer
Slide 5: Pivotal Phase 2b ZEPHYR Study in PWS – Topline Data
5 Pivotal Phase 2b ZEPHYR Study in PWS – Topline Data Livoletide did not meet defined primary endpoint at either dose Change in HQ - CT from baseline at 12 weeks Key Findings: • Larger than expected placebo response • High variability across most HQ - CT measurements • No positive trends observed fo
Slide 6: Thank you for making ZEPHYR possible
6 • Patients • Caregivers • Clinical trial investigators and staff • Millendo team Thank you for making ZEPHYR possible!
Slide 7: Significant Potential Value Creation
Nevanimibe for the treatment of patients with congenital adrenal hyperplasia (CAH), with Phase 2b clinical study ongoing MLE - 301 for menopausal vasomotor symptoms, currently in preclinical studies designed to enable first - in - human clinical studies Experienced leadership team to execute on comp
Slide 8: < oS (e]
< oS (e]
Millendo Therapeutics — Corporate Update (April 2020) on 6ix